Header cover image

Global Pharmaceuticals & Biotech Undiscovered Growth Opportunities

UPDATED Jun 30, 2022

The market has not yet priced in the high-growth prospects for these companies, featuring low PEG ratio (less than 0.5), high future growth outlook and good value on the Snowflake.

21 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
UQ1uniQureUS$17.9219.9%-31.5%US$861.6mUS$51.37PE2.7xE22.6%n/a
84CCleneUS$3.840%-58.7%US$167.6mUS$21.01PE10.1xE82.7%n/a
AVIRAtea PharmaceuticalsUS$7.102.3%-66.7%US$591.1mUS$10.25PE12.2xE45.3%n/a
QUREuniQureUS$18.64-4.6%-40.4%US$869.5mUS$52.95PE2.7xE22.6%n/a
UQ1uniQureUS$17.5322.2%-31.7%US$861.6mUS$50.25PE2.7xE22.6%n/a
CLNNCleneUS$2.52-9.0%-77.4%US$159.4mUS$14.50PE9.6xE82.7%n/a
AYURAyurcann HoldingsCA$0.10-4.8%-51.2%CA$12.1mn/aPE30.3xE138.3%n/a
1061Essex Bio-TechnologyHK$3.900%-46.6%HK$2.2bHK$7.00PE6.5xE21.1%2.8%
3ZQ0Ayurcann HoldingsCA$0.0741.4%-42.5%CA$12.7mn/aPE31.8xE138.3%n/a
VB0Viva Biotech HoldingsHK$0.325.2%-69.3%HK$5.2bn/aPE15.4xE36.0%0%
CRSPCRISPR TherapeuticsUS$60.77-6.7%-61.2%US$4.7bUS$115.30PE15.1xE56.9%n/a
1873Viva Biotech HoldingsHK$2.72-5.9%-72.5%HK$5.2bn/aPE15.4xE36.0%0%
1CGCRISPR TherapeuticsUS$60.530%n/aUS$4.9bUS$110.77PE15.7xE56.9%n/a
VBIZ.FViva Biotech HoldingsHK$0.35-3.8%-72.9%HK$5.2bn/aPE15.4xE36.0%0%
MABMabionzł21.703.3%-68.1%zł350.7mzł26.00PE13.3xE70.6%n/a
AYUR.FAyurcann HoldingsCA$0.081-17.3%n/aCA$12.1mn/aPE30.3xE138.3%n/a
272Mabionzł4.680.5%-69.2%zł358.6mzł5.48PE13.6xE70.6%n/a
X0M1XOMAUS$19.009.2%-33.1%US$233.6mUS$58.07PE19.4xE58.1%n/a
CRSP NCRISPR TherapeuticsUS$1,245.008.4%-60.8%US$4.9bUS$2,278.74PE15.7xE56.9%n/a
XOMAXOMAUS$22.2812.3%-33.5%US$254.5mUS$62.50PE21.1xE58.1%n/a
C2RS34CRISPR TherapeuticsUS$39.510%n/aUS$4.7bUS$74.97PE15.1xE56.9%n/a
Page 1 of 1